India's Panacea Biotec jumps as Phase 3 dengue vaccine trial begins

Panacea Biotec

14/08/2024 10:07

** Shares of Panacea Biotec  PNCA.NS  up 8.7% to 171.95
rupees
    ** Stock hits highest level since mid-Jan this year
    ** The pharma firm and the Indian Council Of Medical
Research initiate phase 3 clinical trial in India with dengue
vaccine DengiAll
    ** Stock last up 3.2%, bringing YTD losses to ~2.6%

 (Reporting by Yagnoseni Das in Bengaluru)
 ((Yagnoseni.Das@thomsonreuters.com;))